A 6 years and 5-month-old girl with Prader-Willi Syndrome (PWS) attends endocrine clinic with her mother. She was first seen by the endocrine team at 18 months old and the referral was made by a geneticist. Mum reports she has been obsessive and extremely challenging with her behaviour around food, and she is concerned about her child’s weight.
A systematic review and meta-analysis suggests that girls with idiopathic central precious puberty who are treated with gonadotropin-releasing hormone analogue therapy may expect to have a higher final adult height and lower BMI than if they do not receive the treatment.
Rare copy number variants have been identified in a study of children who have growth hormone insensitivity or insulin-like growth factor-1 insensitivity, shedding light on the genetic basis of their conditions.
The C-type natriuretic peptide analogue vosoritide significantly increases the growth rate of children with achondroplasia, indicate the results of a randomised, double-blind phase 3 study published in The Lancet.
Webcast now available We are delighted to share the Springer Healthcare IME virtual meeting, entitled Insights into MAnaging Growth for Endocrine Nurses (IMAGE). This was the 7th IMAGE conference whi [...]